Action GSK GLAXOSMITHKLINE PLC
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués GlaxoSmithKline plc LIQUIDNET SYSTEMS

Actions

GSK

GB0009252882

Temps Différé LIQUIDNET SYSTEMS
Autres places de cotation
 		Varia. 5j. Varia. 1 janv.
- EUR -.--% Graphique intraday de GlaxoSmithKline plc -0,40% -.--%
13:18 GSK : UBS maintient sa recommandation à l'achat ZD
09:12 GSK : JP Morgan maintient son opinion vendeuse ZD

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
US FDA approves expanded age indication for GSK's Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk | GSK
AQ
US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
BU
GSK : DO NOT COURIER US FDA approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk
PU
GSK accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies | GSK
AQ
GSK : accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies
PU
Jemperli (dostarlimab) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer | GSK
AQ
GSK : Jemperli (dostarlimab) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer - Form 6-K
PU
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
BU
GSK : Jemperli (dostarlimab) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
PU
GSK : Blenrep combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma - Form 6-K
PU
Statement: Zantac (ranitidine) litigation - Delaware State Court Daubert Ruling - Form 6-K
PU
Statement: Zantac (ranitidine) litigation - Delaware State Court Daubert Ruling | GSK
AQ
Blenrep combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma | GSK
AQ
GSK : Blenrep combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
PU
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
BU
New data at ASCO showcases the transformational potential of GSK's oncology portfolio | GSK
AQ
Statement: Zantac (ranitidine) litigation - Valadez and Williams cases - Form 6-K
PU
New data at ASCO showcases the transformational potential of GSK's oncology portfolio | GSK
AQ
Statement: Zantac (ranitidine) litigation - Valadez and Williams cases | GSK
AQ
GSK : New data at ASCO showcases the transformational potential of GSK's oncology portfolio
PU
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action GSK
  4. Action GSK
  5. Actualités GlaxoSmithKline plc
  6. Communiqués